Caillé P, Mondesir J M, Droz J P, Kerbrat P, Goodman A, Ducret J P, Theodore C, Spielman M, Rouëssé J, Amiel J L
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):901-2.
Forty patients with advanced renal cell carcinoma were treated with elliptinium by a weekly infusion of 100 mg/m2. Of 38 evaluable patients, five had an objective response (13.2%). Average response duration was 8 months (range, 5-11). The major dose-limiting toxic effect was induction of antielliptinium antibodies, with the risk of intravascular hemolysis. Elliptinium has modest activity in advanced renal cell cancer and does not produce myelosuppression.
